Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Ozempic is FDA-approved for treating type 2 diabetes – but could it also help with other conditions like PCOS Read on to find out what an expert says ...

Breaking Into Industry: Career Opportunities for PhD Graduates in Analytical Sciences ...

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an ...

Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle. First, a large-scale real-world study reporting no significantly higher risk of cancer ...